Time point | Enrolment | Allocation | Post-allocation | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
During chemotherapy with or without SBRT | Post-surgery | ||||||||||
1 month | 2 months | 3 months | 4 months | 1 month | 3 months | 6 months | 1 year | 2 years | |||
Enrolment | |||||||||||
 Eligibility screen | X |  |  |  |  |  |  |  |  |  |  |
 Informed consent | X |  |  |  |  |  |  |  |  |  |  |
 Allocation |  | X |  |  |  |  |  |  |  |  |  |
Interventions | |||||||||||
 Gem+nab-paclitaxel |  |  | |||||||||
 Gem+nab-paclitaxel+SBRT |  |  | |||||||||
 S-1 + nab-paclitaxel+SBRT |  |  | |||||||||
Assessments | |||||||||||
 Physical examinations | X |  | X | X | X | X | X | X | X | X | X |
 Laboratory tests | X |  | X | X | X | X | X | X | X | X | X |
 Imaging examinations | X |  |  | X |  | X |  | X | X | X | X |
 cfDNA, CTC a | X |  |  |  |  | Xb |  |  |  |  |  |
 Organoid | X |  |  |  |  |  | X |  |  |  |  |
 DNA sequencing of specimens | X |  |  |  |  |  | X |  |  |  |  |
 Adverse effects |  |  | X | X | X | X | X | X |  |  |  |
 Surgical safety |  |  |  |  |  |  | X | X |  |  |  |
 Survival status |  |  |  |  |  |  |  |  |  | X | X |